December 1-4, 2018

1. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma

2. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in subjects with non-Hodgkin’s lymphoma (NHL)

3. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159

4. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations

December 2-6, 2018

1. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer

December 2-6, 2018

1. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer

March 16-19, 2019

1. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial

2. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study

3. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (≥4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer

4. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC)

April 2020 | Virtual

1. Abstract: Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer

2. Abstract: Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

3. Abstract: Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab

4. Abstract: Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by BRCA and homologous recombination status: PRIMA/ENGOT-OV26/GOG-3012 study

5. Abstract: Time to first subsequent therapy (TFST) and progression-free survival 2 (PFS2) from the phase 3 randomized, double-blind PRIMA/ENGOT-OV26/GOG-3012 study in patients with newly diagnosed ovarian cancer

April 2020 | Virtual

1. Presentation: Time to First Subsequent Therapy (TFST) and Progression-Free Survival 2 (PFS2) From the Phase 3 Randomized, Double-Blind PRIMA/ENGOT-OV26/GOG-3012 Study in Patients With Newly Diagnosed Ovarian Cancer Study SGO 2020

2. Presentation: Efficacy of Niraparib Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer by BRCA and Homologous Recombination Status: PRIMA/ENGOT-OV26/GOG-3012 Study SGO 2020

3. Presentation: Safety and Efficacy of the Anti–PD-1 Monoclonal Antibody Dostarlimab in Patients With Recurrent or Advanced dMMR Endometrial Cancer SGO 2020

4. Presentation: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab SGO 2020

Apr 29-May 3, 2020 | Virtual

1. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

2. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial

3. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative

Apr 27, 2020 | Virtual Annual Meeting I

1. Presentation: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1)

2. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1)

3. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses

4. Poster with Audio: Voice Recording: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses

5. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC

May 29-June 2, 2020 | Virtual

1. ENGOT-OV44/FIRST Study: A Randomized, Double-Blind, Adaptive, Phase 3 Study of Platinum-Based Chemotherapy (CT) ± Dostarlimab Followed by Niraparib ± Dostarlimab Maintenance as First-Line (1L) Treatment of Stage 3 or 4 OC

2. Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC)

3. Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study

4. Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment

5. ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC)

6. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin– Paclitaxel Versus Placebo + Carboplatin–Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer

7. Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2

8. Plain Language Summary [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and DNA Patterns That Are Considered ‘High-Risk’?

9. DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM)

10. DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

11. Plain Language Summary [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function?

12. DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs

13. Plain Language Summary [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments

14. DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

15. INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors

16. INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

17. Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma (HNSCC)

18. ENCORE: Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

19. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E)

20. BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study

21. Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC)

Publication Only: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out?

Publication Only: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting

Publication Only: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab

Publication Only: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)

Publication Only: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma

Publication Only: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review

Publication Only: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS)

Publication Only: Epidemiology of Adenoid Cystic Carcinoma in the United States

May 29-June 2, 2020 | Virtual

1. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

2. Plain Language Summary [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone?

September 7-10, 2019

1. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1)

2. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER

September 7-10, 2019

1. Novel regimens versus standard-of-care in NSCLC: a phase II, randomized, open-label, platform trial using a master protocol

2. Target antigen levels in NSCLC samples define a clinically relevant activation threshold for NY-ESO-1 TCR T-cell therapy